A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
A hacker group who claimed to be behind a cyber attack on Sony Pictures have posted a message online apparently mocking the FBI.
The returns of Benedict Cumberbatch's detective and the X Factor judge were among 2014's most tweeted TV moments in a billion conversations.
A family has issued an appeal to help find their missing pet turkey - in case he gets gobbled up as someone's Christmas dinner.